Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review

• Published in: Brachytherapy Vol. 23; no. 2; pp. 141 - 148
• Main Authors: Parikh, Shreel, Zhang, Yingting, Sherwani, Zohaib, Kumar, Ritesh, Ohri, Nisha, Jan, Imraan, Vergalasova, Irina, Jabbour, Salma, Hathout, Lara
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-03-2024
• Subjects: Brachytherapy; Brachytherapy - methods; Communicable Disease Control; COVID-19; Female; Global; Humans; Male; Pandemic; Pandemics; Prospective Studies; Prostatic Neoplasms - radiotherapy; Retrospective Studies; Systematic review; Uterine Cervical Neoplasms; RT; OR; Systematic review; Pandemic; IST; Global; OTT; SA; PCa; COVID-19; BT; MA; Brachytherapy; IC
• ISSN: 1538-4721; 1873-1449; 1873-1449
• DOI: 10.1016/j.brachy.2023.11.002

To assess the impact of the COVID-19 pandemic on the use of brachytherapy in patients with gynecologic and prostate cancers including treatment delays, increased burden of mortality, and associated clinical outcomes.
A comprehensive search of PubMed, Cochrane Library, CINAHL, Scopus, and Web of Science was conducted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases were searched for studies published through September 2023 using MeSH terms and keywords related to “COVID and brachytherapy.” Inclusion criteria included all studies reporting on the impact of COVID-19 on treatment delay, treatment omission, recurrence rates, and clinical outcomes in patients requiring brachytherapy for prostate or gynecologic cancers from December 2019 to September 2023. Data were extracted by two independent reviewers (LH, IV).
Of the 292 screened records, 10 studies (9 retrospective, 1 prospective single-arm exploratory noninferiority) were included. Hypofractioned regimens were the preferred approach in radiation treatment (RT) centers, with 6 of 10 studies noting shift towards hypofractionation. For cervical cancer, intracavitary brachytherapy was limited to 3–4 fractions, reducing personnel and patient exposure. Treatment delays influenced by COVID-19 ranged between 19% and 53% and treatment omissions ranged between 2% and 28%. These disruptions arose from factors such as patient fear of contracting COVID-19, COVID-19 infection, barriers to accessing care, and operating room closures. Three studies reported on a single-application (SA) rather than a multiple application (MA) approach for cervical cancer. They reported excellent local control, shorter overall treatment time at the expense of higher grade ≥2 vaginal, genitourinary, and gastrointestinal events. For cervical cancer patients, overall treatment time (OTT) was significantly impacted by COVID-19 as reported by 2 studies from India. OTT > 60 days occurred in 40–53% of patients.
This is the first systematic review to assess the impact of the COVID-19 pandemic on brachytherapy in patients with gynecologic and prostate cancers. Although many expert consensus recommendations have been published during the pandemic regarding radiation therapy, few studies evaluated its clinical impact on brachytherapy delivery and patient outcomes. The COVID-19 pandemic resulted in treatment delays, omissions in brachytherapy, and further adoption of hypofractionated regimens. Early results demonstrate that despite increased toxicities, local control rates with hypofractionated treatment are similar to standard fractionation. The impact of the pandemic on gynecologic and prostate cancers is yet to be determined as well as the long-term outcomes on patients treated during the lockdown period.